Vancomycin-intermediate Staphylococcus aureus isolates are attenuated for virulence when compared with susceptible progenitors

被引:19
|
作者
Cameron, D. R. [1 ,2 ]
Lin, Y. -H. [3 ]
Trouillet-Assant, S. [4 ]
Tafani, V. [4 ]
Kostoulias, X. [1 ,2 ]
Mouhtouris, E. [5 ]
Skinner, N. [6 ]
Visvanathan, K. [6 ]
Baines, S. L. [3 ]
Howden, B. [3 ]
Monk, I. R. [3 ]
Laurent, F. [4 ]
Stinear, T. P. [3 ]
Howden, B. P. [3 ,7 ,8 ]
Peleg, A. Y. [1 ,2 ,9 ,10 ]
机构
[1] Monash Univ, Monash Biomed Discovery Inst, Infect & Immun Program, Melbourne, Vic, Australia
[2] Monash Univ, Dept Microbiol, Melbourne, Vic, Australia
[3] Univ Melbourne, Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia
[4] Hosp Civils Lyon, Int Ctr Infectiol Res, French Natl Reference Ctr Staphylococci, Dept Microbiol, Lyon, France
[5] Univ Melbourne, Dept Surg, Melbourne, Vic, Australia
[6] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
[7] Austin Hlth, Infect Dis Dept, Melbourne, Vic, Australia
[8] Austin Hlth, Microbiol Dept, Melbourne, Vic, Australia
[9] Monash Univ, Alfred Hosp, Dept Infect Dis, Melbourne, Vic 3004, Australia
[10] Monash Univ, Cent Clin Sch, Melbourne, Vic 3004, Australia
基金
英国医学研究理事会;
关键词
Accessory gene regulator agr; alpha toxin; Persistence; Staphylococcus aureus; Vancomycin-intermediate Staphylococcus; aureus; Virulence; REDUCED SUSCEPTIBILITY; ANTIBIOTIC-RESISTANCE; ALPHA-HEMOLYSIN; IN-VIVO; MUTATION; AGR; INFECTION; BACTEREMIA; ACTIVATION; EVOLUTION;
D O I
10.1016/j.cmi.2017.03.027
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: Vancomycin-intermediate Staphylococcus aureus (VISA) is associated with genetic changes that may also impact upon pathogenicity. In the current study, we compared the virulence of clinical VISA strains with their isogenic vancomycin-susceptible progenitors (VSSA). Methods: Production of the critical virulence protein, a toxin, was assessed using Western blot analysis and was correlated to agr activity using a bioluminescent agr-reporter. Cytotoxicity and intracellular persistence were compared ex vivo for VSSA and VISA within non-professional phagocytes (NPP). Virulence and host immune responses were further explored in vivo using a murine model of bacteraemia. Results: VISA isolates produced up to 20-fold less alpha toxin compared with VSSA, and this was corroborated by either loss of agr activity due to agr mutation, or altered agr activity in the absence of mutation. VISA were less cytotoxic towards NPP and were associated with enhanced intracellular persistence, suggesting that NPP may act as a reservoir for VISA. Infection with VSSA strains produced higher mortality in a murine bacteraemia model (>= 90% 7-day mortality) compared with infection with VISA isolates (20% to 50%, p<0.001). Mice infected with VISA produced a dampened immune response (4.6-fold reduction in interleukin-6, p<0.001) and persistent organ bacterial growth was observed for VISA strains out to 7 days. Conclusions: These findings highlight the remarkable adaptability of S. aureus, whereby, in addition to having reduced antibiotic susceptibility, VISA alter the expression of pathogenic factors to circumvent the host immune response to favour persistent infection over acute virulence. (C) 2017 The Authors. Published by Elsevier Ltd
引用
收藏
页码:767 / 773
页数:7
相关论文
共 50 条
  • [11] Low Prevalence of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates among Connecticut Veterans
    Fink, Susan L.
    Martinello, Richard A.
    Campbell, Sheldon M.
    Murray, Thomas S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (01) : 582 - 583
  • [12] A Novel δ-Hemolysis Screening Method for Detecting Heteroresistant Vancomycin-Intermediate Staphylococcus aureus and Vancomycin-Intermediate S-aureus
    Cafiso, V.
    Bertuccio, T.
    Spina, D.
    Purrello, S.
    Blandino, G.
    Stefani, Stefania
    JOURNAL OF CLINICAL MICROBIOLOGY, 2012, 50 (05) : 1742 - 1744
  • [13] Septic arthritis caused by vancomycin-intermediate Staphylococcus aureus
    Lu, JJ
    Lee, SY
    Hwa, SY
    Yang, AH
    JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (08) : 4156 - 4158
  • [14] Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant Staphylococcus aureus
    Capin, Busra Betul Ozmen
    Tekeli, Alper
    Karahan, Zeynep Ceren
    MICROBIAL DRUG RESISTANCE, 2020, 26 (03) : 238 - 244
  • [15] Reconstruction of the Vancomycin-Susceptible Staphylococcus aureus Phenotype From a Vancomycin-Intermediate S. aureus XN108
    Peng, Huagang
    Rao, Yifan
    Yuan, Wenchang
    Zheng, Ying
    Shang, Weilong
    Hu, Zhen
    Yang, Yi
    Tan, Li
    Xiong, Kun
    Li, Shu
    Zhu, Junmin
    Hu, Xiaomei
    Hu, Qiwen
    Rao, Xiancai
    FRONTIERS IN MICROBIOLOGY, 2018, 9
  • [16] Selection of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus by Imipenem
    Katayama, Yuki
    Murakami-Kuroda, Hiroko
    Cui, Longzhu
    Hiramatsu, Keiichi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (08) : 3190 - 3196
  • [17] Survival of vancomycin-intermediate Staphylococcus aureus on hospital surfaces
    Zarpellon, M. N.
    Gales, A. C.
    Sasaki, A. L.
    Selhorst, G. J.
    Menegucci, T. C.
    Cardoso, C. L.
    Garcia, L. B.
    Tognim, M. C. B.
    JOURNAL OF HOSPITAL INFECTION, 2015, 90 (04) : 347 - 350
  • [18] Biofilms: A developmental niche for vancomycin-intermediate Staphylococcus aureus
    Chapman, Jenelle E.
    George, Shilpa E.
    Wolz, Christiane
    Olson, Michael E.
    INFECTION GENETICS AND EVOLUTION, 2024, 117
  • [19] Synergy of flavone with vancomycin and oxacillin against vancomycin-intermediate Staphylococcus aureus
    Bakar, Nur Salwani
    Zin, Noraziah Mohamad
    Basri, Dayang Fredalina
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 25 (03) : 633 - 638
  • [20] A novel mutation of walK confers vancomycin-intermediate resistance in methicillin-susceptible Staphylococcus aureus
    Zhu, Jiade
    Liu, Banghui
    Shu, Xueqin
    Sun, Baolin
    INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2021, 311 (02)